Actively Recruiting
TaVNS Improves the Symptoms of Patients With Moderate to Severe CP/CPPS
Led by Jiani Wu · Updated on 2025-11-28
68
Participants Needed
1
Research Sites
152 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This trial aims to evaluate the efficacy and safety of transcutaneous auricular vagus nerve stimulation (taVNS) for moderate to severe chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS). This study is a prospective, randomized, controlled trial. A total of 68 patients with CP/CPPS will be recruited. After baseline assessment, the patients will be randomized into taVNS group (n = 34) and sham-taVNS group (n = 34). The intervention of two group will last for 4 weeks with a 8-week follow-up period after the treatment. The National Institutes of Health chronic Prostatitis Symptom Score index (NIH-CPSI), International Prostate Symptom Score Scale (IPSS), European quality of Life-5 Dimensions Questionnaire (EQ-5D), self-rating anxiety Scale (SAS) and self-rating depression scale (SDS) will be assessed. The adverse events during the whole study will be recorded detailedly.
CONDITIONS
Official Title
TaVNS Improves the Symptoms of Patients With Moderate to Severe CP/CPPS
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Male patients aged 18 to 50 years
- Diagnosed with moderate to severe chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) based on EAU or CAU criteria
- Symptoms include recurrent and persistent prostate pain with abnormal urination and neuropsychiatric symptoms lasting more than 3 months in the last 6 months
- NIH-CPSI score of 15 or higher
- Signed informed consent and willing to participate in the trial
You will not qualify if you...
- Presence of other diseases causing urinary symptoms such as benign prostatic hyperplasia, testicular or epididymal diseases, overactive bladder, neurogenic bladder, interstitial cystitis, sexually transmitted diseases, bladder tumors, prostate cancer, urinary tuberculosis, anorectal diseases, lumbar diseases, or neuropathies
- Severe heart, liver, kidney, or hematopoietic system diseases or poor nutritional status
- Severe mental or emotional disorders preventing cooperation
- Received treatment for CP/CPPS in the past 4 weeks
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Guang'anmen Hospita, China Academy of Chinese Medical Sciences
Beijing, Beijing Municipality, China, 100053
Actively Recruiting
Research Team
J
Jiani Wu
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here